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MELANOMA
A PHASE I TRIA L OF H IG H  D O SE T A M O X IFE N  (TA M ) AND 
WEEKLY C 1 SPLA TIN  (D D P) IN TH E T R E A T M E N T  O F 
M ETASTATIC M E L A N O M A . E.F. M e C lav . M .E. Me Clay. J. A.
Jones. P. J. W in sk i. M e la n o m a  C en te r , H o llin g s  C an ce r  
Center. D iv is io n  o f  H e m a to lo g y /O n c o lo g y ,  D e p a r tm e n t  o f  
M edicine. M e d ica l  U n iv e rs i ty  o f  S o u th  C a ro lin a  . C h a rle s to n . 
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W e have  p re v io u s ly  d e m o n s tra te d  th a t T A M  is 
synerg istic  w ith  D D P  in  c l in ic a l  t r ia ls  in p a t ie n ts  w ith  
m ctasta tic  m e lan o m a . In th e  la b o ra to ry  w c  h a v e  
dem onstra ted  th a t th is  s y n e rg y  is d e p e n d e n t  u p o n  a T A M  
cffcct th a t  is c u r re n tly  u n d e r  in v e s t ig a t io n .  T o  d a te  w e  h a v e  
shown th a t i t  is  not th e  re su lt  o f  a  T A M  e ffec t on  an y  o f  the  
known m e c h a n ism  o f  D D P  re s is ta n c e . In th e  la b o ra to ry  T A M  
will m ake s e n s i t iv e  ce lls  m o re  s e n s i t iv e ,  D D P  re s is ta n t  ce ll  
sensitive and  w il l  a lso  in te r fe re  w ith  th e  a b il i ty  o f  the. 
tumor ce lls  to  d ev e lo p  re s is ta n c e  to  D D P . In o rd e r  to im p ro v e  
upon th e  c o m p le te  re s p o n s e  ra te  o f  th is  re g im e n  w e 
initiated a p h a se  I tr ia l  e v a lu a t in g  th e  o b je c t iv e  re sp o n se  
rate in p a tien ts  tre a ted  w i th  in c re a s in g  d o ses  o f  T A M  in  
com bination  w ith  a  w e e k ly  d o se  o f  D D P  ( 8 0 m g /M 2). P a t ie n ts  
were trea ted  w e ek ly  fo r  3  w e e k s , g iv e n  a 2  w e ek  rest, th en  
treated w eek ly  X  3  ag a in . R e sp o n se  e v a lu a t io n  o ccu rred  a t 4  
and 9  w eeks a f te r  th e  s ta r t  o f  th e rap y . T h e  s ta r t in g  d o se  o f  
TAM w as 1 6 0  m g /day  an d  has b een  in c re a se d  to a  c u rre n t 
dose o f  3 2 0  m g /day . N o  re sp o n se s  w e re  o b se rv e d  in p a tie n ts  
treated at T A M  doses  le ss  th an  2 4 0  m g. In 7  p a tien ts  tre a ted  
above th is dose  th e re  has b e e n  1 C R , 2  P R 's , I p ro g re ss iv e  
disease and  2  too  ea rly  to  d e te rm in e . T o x ic ity  has been 
prim arily  h e m a to lo g ic  in  n a tu re  a t th e  h ig h e r  d o se s . T h e re  
have been  no e p iso d e s  o f  th ro m b o s is  to da te . C o rre la t iv e  
laboratory s tu d ie s  o f  D D P  an d  T A M  p h a rm a c o k in e tic s  as  
well as seria l ev a lu a tio n s  o f  th e  e f fe c t  o f  T A M /D D P  on th e  
expression o f  G A D D  1 5 3  a n d  p 5 3  a re  in p ro g ress . S u p p o rted  
by N IH  gran t C A  5 2 1 5 1 .
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PREDICTORS OF LONG-TERM SURVIVAL IN STAGE IV MELANOMA.
SJ Frank, R Rellmann, J Applewhite, AN Houghton, and ML Movers. 
Memorial Sloan-Kettetfng Cancer Center, NY, NY 10021.
Retrospective analyses have identified pre-treatment clinical prognostic 
factors that accurately predict survival In patients with AJCC stage IV 
melanoma. These studies typically employ median survival as the dependent 
variable or utilize a fully parametric survival regression model.
To provide patients with more meaningful prognostic Information and 
to facilitate decision-making by the clinician, we have analyzed the categorical 
variable long-term survival" (defined as survival for at least three years after 
the date of tne first distant metastasis). A cohort of 25 long-term survivors 
(LTS) has been Identified among the patients with stage IV melanoma seen at 
Memorial Sloan-Kettering Cancer Center (MSKCC). The control group 
consisted of 160 patients seen at MSKCC durina the same period who were 
known to have survived less than 3 years after diagnosis of stage IV disease.
The median age of the LTS was 49. S years, compared to 57.5 years 
for the controls. Of the LTS, 52% were females, compared to 35% of the 
controls. These differences were not statistically significant. Other 
characteristics of the LTS were as follows: The primary site was an extremity 
in 28%, the trunk In 28%, and head and neck In 12%; Interestingly. 32% had 
an unknown primary site. 48% had presented initially with stage I or II, 24% 
with stage III, and 28% with stage IV disease. The Initial metastatic site was 
lung only In 28% and brain only In 8%. Median disease-free Interval prior to 
diagnosis of stage IV disease was 39 months for patients with prior stage I or 
II disease and 34.8 months for those with prior stage III disease. None of 
these characteristics differed significantly between the LTS and the patients 
surviving for less than three years.
Interestingly, the number of metastatic sites did not differ between the 
LTS and the controls. However, among the LTS, 14/25 (56%) had been 
rendered disease-free by initial therapy for their stage IV disease; 9 had 
undergone complete surgical resection, and 5 had achieved a complete 
response (CR) to chemotherapy. In addition, 5 LTS patients had achieved 
Initially a partial response (PR) (1 to chemotherapy, 2 to Immunotherapy, and 
2 by surgical resection). Data on response to Initial therapy were available for 
100 of the controls. Only 15/100 (15%) had been rendered disease-free (14 
by surgery and 1 by Immunotherapy); 4 .of the controls had achieved a PR (3 
to chemotherapy and 1 to Immunotherapy). Thus, the LTS were more likely 
to have undergone a complete resection of their metastases than were the 
controls (36% vs. 14%; p=0,019), And, the LTS were also more likely to have 
achieved a CR or PR wltn Initial chemotherapy or Immunotherapy (40% vs. 5%; 
p <0,0001). (Supported by grant CA-09207-18.)
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COMBINATION C H EM O TH ER A PY  T O G E T H E R  W IT H  INTERFERON- 
ALPHA (IFNa) TN M ETA STA TIC  M ELA N O M A  (MM), A M U LTICEN TER 
PHASE II  STUDY. Punt CJA1. Jansen RLH2, Vreugdenhil A1, De Mulder 
PHM1, 1 . Dept, o f Medical Oncology, University Hospital Nijmegen, 2, Univer­
sity Hospital Maastricht, 3 . St. Joseph Hospital Veldhoven, The Netherlands.
Chemoimmunotherapy with dacarbazine (DTIC), vincristine (VCR), bleomycin 
(BLM), lomustine (CCNU) and IF N a has shown a promising response rate of 
6 2 % in 4 5  patients (pts) with M M  (Pyrhdnen et a!. JCO 1 0 :1 9 1 9 ,1 9 9 2 ). We 
started a multicenter phase II study in order to confirm these results. Treatment 
consisted of DTIC 2 0 0  mg/m 7  d l - 5 , VCR 1  mg/m7  d l + 4 , BLM 1 5  mg d 2 + 5 , 
CCNU 8 0  mg orally d l ,  q 4  weeks. IFNor-2 b (Schering Plough, Amstelveen) 
was started on d 8  at 3 x 1 0 * U daily s.c, for 6  weeks, and thereafter f ijd tf  U 
t.i.w. Inclusion criteria included measurable non* resec table M M , age 1 8 - 7 5  Yrs,I I 1
PS ¿ 2 , systemically pretreated 5 1  regimen, no steroid use. Pts were evaluated 
every 2  months for response, and weekly for toxicity. Currently 2 3  pts are 
entered and 1 8  are evaluable. One pt died on day 5  o f  treatment of unknown 
cause and is not included in the response evaluation. Five pts are too early. Pts 
characteristics are male/female 1 1 / 7 , median age 5 7  yrs (3 3 -7 4 ), median PS 1 (0 - 
2 ). Sites of metastases were skin 1 1 , lymph nodes 1 0 , lung 9 , liver 9 , bone 2 , 
brain 4 , other 7  pts. Median number o f  metastatic sites was 4  ( 1 -5 ). Prior 
treatment: surgery for metastases 8 , radiotherapy 5 , chemotherapy 2 , immu­
notherapy 3  pts. Pts received a median of 4  ( 1 -6 ) cycles. Seven pts achieved a 
PR (RR 4 1 %, 9 5 %CI 1 8 9 &-6 7 %), all systemically not pretreated, 3  pts SD and 7  
pts PD. Two PR occurred in pts with previously irradiated brain metastases. 
Progression with brain metastases occurred in 5  out o f  9  pts without initial brain 
metastases. In 4  pts with PD after 2 - 4  cycles in whom chemotherapy was 
continued but IFNot was interrupted every 2  wks for 2  wks no response was 
seen, which is in contrast to previous observations. Median duration o f  response 
and survival are in excess o f  5  months. Toxicity grade &III (WHO) consisted of 
fatigue 7  pts, anorexia 5 , leucocytopenia 4 , flu-like symptoms 2 , nausea/vomiting 
I, pulmonary fibrosis 1 , neurotoxicity 2 , and death 1 . Doses were reduced in 8  
pts. We conclude that this regimen is active in pts with metastatic melanoma with 
high-volurae disease. In pts with brain metastases, prior radiotherapy is recom­
mended. Toxicity may be substantial, but this schedule is feasible in an outpatient 
setting. Accrual will continue, and updated results will be presented.
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ROLE OF CT SCANS IN THE STAGING OF MELANOMA 
PATIENTS WITH LOCAL/REGIONAL DISEASE. A.C. Buzaid. L. 
Tinoco, M. Ross, S. Legha, R. S. Benjamin. The University of Texas 
M. D, Anderson Cancer Center. Houston, TX 77030.
Introduction: We have previously shown that CT scans of the 
brain, chest, abdomen and pelvis have a low yield in detecting occult 
metastases (mets) in patients (pts) with primary melanoma (J Clin 
Oncol 11:638,1993). Objecti ve. To study the value of CT scans in the 
staging of melanoma pts with local/regional disease. Methods: 
Retrospective review of the records of 99 pts who presented with or 
developed as first site of recurrence nodal or intransit mets or local 
recurrence. Pts were categorized into four groups: true positive (TP), 
when the scan identified either regional or distant disease which was 
not appreciated on physical examination; false positive (FP), when the 
scan revealed a radiologic abnormality which either did not change for 
at least 6 months or was proven to be histologically benign; false 
negative (FN), when a pt had symptoms suspicious for mets and was 
subsequently found to have mets, but all imaging studies were 
nondiagnostic; true negative (TN), when all imaging studies were 
negative for mets in a asymptomatic pt. Results: TP - 11 pts, FP - 21 
pts, FN -1 pt, and TN - 66 pts. Of the 11 pts with TP Findings, only 2 
were symptomatic. Lung mets were identified in 5 but in only 2 the 
chest CT identified disease which was not visible on chest-X-ray 
(CXR). CT of the abdomen or pelvis revealed mets in 5 pts. CT of the 
pelvis, however, was normal in all 32 pts with recurrent disease above 
the waist line. CT or MRI of the brain showed no evidence of brain 
mets in any patient, although it showed asymptomatic skull mets in 1. 
The most common FP finding^ were hypodense hepatic lesions and 
nnncalcified lung nodules. Conclusion: 1) TP are observed in about 
10% of the pts. Because FP are more common than TP findings, 
histologic diagnosis of recurrence is advisable; 2) CT or MRI of the 
brain are not necessary in asymptomatic pts; 3) chest CT adds very 
little to a CXR and is not routinely indicated. In light of the cost- 
conscious environment of the current health-care system, our results 
are of practical importance.
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